Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
We cover the top budgeting pitfalls and simple methods to prevent them, helping you maintain accuracy and momentum in your plan.
17,089 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Li Lu’s Himalaya Capital places a near alarmingly large bet on Alphabet, powering a dramatic year for the fund and re...
Insider moves can signal a lot about a company’s near-term plans and risk. This deep dive looks at Adaptive Biotechno...
Goldman Sachs' latest research paints a paradox: trillions are pouring into AI infrastructure, but returns remain mur...
A deep dive into a sleeper AI infrastructure stock that could gain as data centers demand faster, cleaner connectivit...
Beyond Meat faces a double headwind: a tepid forecast and a crowded protein-drink market. Investors are reeling as re...
Amazon trimmed 16,000 jobs in early 2026, even as CEO Jeff Bezos warned AI could create a labor shortage. The clash b...
Rand Capital's Q1 2026 earnings set the tone for the year. This analysis breaks down the numbers, portfolio quality, ...
Samara unveils Locale by Samara, its first single-family model in California, aiming to ease housing shortages by bui...
Investors often ask where XRP will be in three years. This article examines bear, base, and bull scenarios, plus prac...
Public zoning records can be helpful for planning, but they also attract scammers. This article explains how those de...
Ethereum sits in a tight range while on-chain tokenized Treasuries on the network surpass $8 billion, marking a major...